TNF and inflammatory bowel disease: The VEGA trial used guselkumab and golimumab naive to an anti-TNF and refractory or intolerant to conventional therapy.18 While golimumab is approved for the treatment of IBD, it is rarely used and was not used within our cohort, and guselkumab has not been approved by the FDA for the treatment of IBD.